Finerenone is a medication being studied for its safety when used long-term in children and young adults with chronic kidney disease and proteinuria. It is taken orally and is adjusted based on age and body weight. The goal is to see if it can be safely added to other treatments for kidney disease.

ACEI (Angiotensin-Converting Enzyme Inhibitors) are medications that help relax blood vessels and reduce blood pressure. They are commonly used to treat conditions like high blood pressure and heart failure. In this study, they are used alongside finerenone to manage chronic kidney disease.

ARB (Angiotensin II Receptor Blockers) are another type of medication that helps lower blood pressure by blocking the action of a natural chemical that narrows blood vessels. Like ACEIs, ARBs are used in this study with finerenone to treat chronic kidney disease in young patients.

Chronic Kidney Disease – Chronic kidney disease is a long-term condition where the kidneys gradually lose their ability to filter waste and excess fluids from the blood. This can lead to a buildup of waste products in the body, causing symptoms like fatigue, swelling, and changes in urination. Over time, the disease can progress to more severe stages, potentially affecting other organs and systems. The progression is often slow, and symptoms may not appear until significant kidney damage has occurred. Management focuses on slowing the progression and addressing symptoms.

Proteinuria – Proteinuria is a condition characterized by the presence of excess protein in the urine, which can be a sign of kidney damage. Normally, kidneys filter waste while retaining essential proteins in the blood, but when damaged, they may allow proteins to leak into the urine. This condition can be a result of various underlying health issues, including chronic kidney disease. It may not cause noticeable symptoms initially, but over time, it can lead to swelling and other complications. Monitoring and managing proteinuria is crucial to prevent further kidney damage.